NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO
All resolutions were made in accordance with the proposals from the board of directors and the nomination committee, including, but not limited to, approval of the 2023 annual accounts, election of members to the board of directors and the authorisations to the board of directors, and several matters relating to the rights issue to be carried out in the Company to raise gross proceeds of up to approximately
The minutes from the annual general meeting are attached hereto and will also be made available on the Company's website http://www.circio.com under the heading "Investors".
The full terms and conditions for the Rights Issue is included in a prospectus, comprising of a registration document supplement, a securities note and a summary, all dated
For further information, please contact:
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Phone: +34 683343811
Email: lubor.gaal@circio.com
About Circio Holding ASA
Building next generation RNA therapeutics
Circio Holding ASA is a biotechnology company developing novel circular RNA gene therapies and immunotherapy medicines.
Circio has established a unique circular RNA (circRNA) platform for genetic medicine. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed in multiple disease settings. The circVec platform has demonstrated enhanced and more durable protein expression than classic mRNA vector systems, and has the potential to become the new gold-standard for DNA and virus-based therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary
In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in three clinical trials: RAS-mutated pancreatic cancer and lung and non-resectable pancreatic cancer in US, and multiple myeloma in
This information is subject to disclosure under the Norwegian Securities Act section 5-12 and the requirements of Oslo Børs' Continuing Obligations.
***
- IMPORTANT INFORMATION -
This announcement is not and does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of the Company in
The securities of the Company have not been, and will not be, registered under the
Any offering of the securities referred to in this announcement will be made by means of a prospectus (the "Prospectus") which will be prepared and which is subject to the approval by the
In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State.
In the
This document is not for publication or distribution in, directly or indirectly,
Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "anticipate", "believe", "continue", "estimate", "expect", "intends", "may", "should", "will" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice. This announcement is made by and is the responsibility of, the Company. Neither the Manager nor any of its affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein.
This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy, fairness or completeness. Neither the Manager nor any of its affiliates accepts any liability arising from the use of this announcement.
https://news.cision.com/circio/r/circio-holding-asa---minutes-from-the-annual-general-meeting-2024-and-approval-of-rights-issue,c4004300
https://mb.cision.com/Public/17093/4004300/8ca53a63c3aa6af4.pdf
(c) 2024 Cision. All rights reserved., source